Abstract
Newer studies raise concern that adjuvant anthracycline treatment for breast cancer (BC) causes long-term heart damage. We aimed to examine whether heart failure or impairment could be demonstrated several years after low-dose epirubicin-based adjuvant treatment.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Acta Oncologica |
Vol/bind | 51 |
Udgave nummer | 8 |
Sider (fra-til) | 1054-61 |
Antal sider | 8 |
ISSN | 0284-186X |
DOI | |
Status | Udgivet - 2012 |